由 jpichiban 京都大学计划在2025年开始对1型糖尿病患者进行临床试验，使用由iPS细胞培养的胰脏细胞膜进行移植。该方法旨在通过移植的胰脏细胞膜产生胰岛素，降低患者血糖水平，从而减少注射胰岛素的次数，减轻患者负担。研究团队预计该技术将在2030年后实现实用化。这项研究有望解决目前1型糖尿病患者面临的治疗困境，为患者提供新的治疗选择。
Original Title: 京都大学将用iPS细胞治疗糖尿病
Summary: Kyoto University is planning to start clinical trials in 2025 to transplant pancreatic cell membranes cultured from iPS cells into patients with type 1 diabetes. The method aims to lower blood glucose levels by producing insulin from the transplanted pancreatic cell membranes, reducing the number of insulin injections and relieving the burden on patients. The research team expects the technology to be practical after 2030. This research is expected to solve the treatment dilemma faced by current type 1 diabetes patients and provide new treatment options for them.
Original article: http://cn.nikkei.com/industry/scienceatechnology/56587-2024-09-03-09-34-59.html?print=1